Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
NCT02216409 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2019-02-05
Summary
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Conditions
Interventions
- DRUG
-
Hu5F9-G4
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Chris Takimoto, MD · Gilead Sciences
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-08-31
- Primary Completion
- 2018-10-31
- Completion
- 2018-12-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT03128164 ·Status: COMPLETED ·Phase: PHASE1
-
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
NCT07343934 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01190449 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
NCT00854126 ·Status: COMPLETED ·Phase: PHASE1
-
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
NCT06487624 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
NCT05155839 ·Status: UNKNOWN ·Phase: PHASE1
-
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718 ·Status: RECRUITING ·Phase: PHASE1
-
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
NCT01111526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244 ·Status: TERMINATED ·Phase: PHASE1
-
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
NCT02988817 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00004101 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
NCT00575068 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
NCT04379167 ·Status: UNKNOWN ·Phase: PHASE2
-
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00516217 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00667615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
NCT06474481 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
NCT05293912 ·Status: TERMINATED ·Phase: PHASE1
-
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
NCT06918015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
NCT05110742 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
NCT02109224 ·Status: TERMINATED ·Phase: PHASE1
-
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
NCT05299164 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
NCT04761198 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
NCT00562380 ·Status: COMPLETED ·Phase: PHASE1
-
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
NCT05144347 ·Status: TERMINATED ·Phase: PHASE1